Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 278

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 278
---

  
    Accumulated Other Comprehensive Income 
     135,471  
     135,561 
  
    Accumulated Deficit 
     (40,527,957) 
     (32,580,850)
  
    60P Shareholders’ Equity: 
     4,035,600  
     4,870,134 
  
    Noncontrolling Interest 
     (80,594) 
     (72,038)
  
    Total Shareholders’ Equity 
     3,955,006  
     4,798,096 
  
    Total Liabilities and Shareholders’ Equity 
    $5,759,345  
    $7,783,771 

(1)Periods presented have been adjusted to reflect the 1:12 reverse stock split on August 12, 2024 and the 1:5 reverse stock split on February 24, 2025.

See accompanying notes
to these consolidated financial statements which are an integral part of these consolidated financial statements.

F-3

60 DEGREES PHARMACEUTICALS,
INC. 

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
LOSS

    For the Years Ended December
    31, 

    2024  
    2023 
  
    Product Revenues – net of Discounts and Rebates 
    $607,574  
    $253,573 
  
    Cost of Revenues 
     384,765  
     474,550 
  
    Gross Profit (Loss) 
     222,809  
     (220,977)
  
    Research Revenues 
     73,771  
     - 
  
    Net Revenue (Loss) 
     296,580  
     (220,977)

    Operating Expenses: 

    Research and Development 
     4,986,526  
     691,770 
  
    General and Administrative Expenses 
     5,024,985  
     4,241,836 
  
    Total Operating Expenses 
     10,011,511  
     4,933,606 

    Loss from Operations 
     (9,714,931) 
     (5,154,583)

    Interest Expense 
     (7,912) 
     (2,286,637)
  
    Derivative Expense 
     -